1. Scrip
  2. >>Leadership

Seagen Taps Epstein As New CEO After A Tumultuous Year

 
• By Joseph Haas

Former Novartis executive and venture capitalist David Epstein will step in to lead Seagen after its founder resigned in a scandal and amid M&A speculation.

New CEO
Former Novartis exec David Epstein will step in as new Seagen CEO • Source: Shutterstock

Antibody-drug conjugate specialist Seagen Inc. may have concluded a tumultuous period of several months on 10 November, naming veteran industry executive David Epstein as its new CEO to replace interim chief Roger Dansey, who took over following the sudden departure in May of founder and former CEO Clay Siegall.

Amid the leadership uncertainty, Seagen was speculated to be in merger negotiations with Merck & Co., Inc., with which it already had a partnership

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Scrip

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.